{"filings":[{"id":68723,"accession_number":"0000950103-26-007158","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2026-05-13T20:22:27+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q1: PAPZIMEOS nets $21.6M revenue; loss narrows to $7.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue from PAPZIMEOS was $21.6M in Q1 2026, first full quarter post-FDA approval.","Net loss narrowed to $7.9M ($0.02/share) from $54.2M ($0.18/share) in Q1 2025.","Patient hub enrollment reached ~400 patients; 25% from community settings.","Cash, equivalents, and investments totaled $56.7M as of March 31, 2026.","Permanent J-code (J3404) assigned effective April 1, 2026, expected to streamline access."],"consensus_eps_estimate":-0.0326,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":23252000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103207,"accession_number":"0000950103-26-004648","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen posts FY2025 net loss of $1.37/sh; PAPZIMEOS Q4 revenue $3.4M, launch momentum strong","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PAPZIMEOS generated $3.4M in net product revenue in Q4 2025, first partial quarter of US commercial sales.","Cash, cash equivalents, and investments $100.4M as of Dec 31, 2025, expected to fund to cash flow break-even.","Patient hub enrollment >300; payer coverage ~215M lives (~90% insured US); CMS assigned permanent J-code effective Apr 1, 2026.","Net loss attributable to common shareholders $429.6M ($1.37/sh) vs $126.2M ($0.47) in 2024, driven by non-cash warrant and preferred stock items.","R&D expenses down 22.1% YoY; SG&A up 69.8% reflecting commercial launch investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119444,"accession_number":"0000950103-25-014683","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Reports Q3 2025 Financial Results; PAPZIMEOS Full FDA Approval in August","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["PAPZIMEOS (zopapogene imadenovec-drba) received full FDA approval in August 2025 for adults with RRP.","Over 100 patients registered in PAPZIMEOS Patient Hub; more than 100 million lives covered by private insurance.","Submitted Marketing Authorization Application to EMA for zopapogene imadenovec in November 2025.","Cash, cash equivalents, and investments totaled $123.6 million as of September 30, 2025.","Entered credit facility providing up to $125 million non-dilutive financing; received first tranche of $100 million."],"consensus_eps_estimate":-0.0969,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136003,"accession_number":"0000950103-25-011775","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-09-17T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Precigen: $79M Preferred Stock converted into 54.9M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders converted 79,000 shares of 8.00% Series A Convertible Preferred Stock (stated value $79M) into 54,937,411 common shares.","Conversion rate: 695.4103 common shares per $1,000 of Preferred Stock stated value, delivered on Sept 17, 2025.","Shares issued in reliance on Section 3(a)(9) exemption; no commission paid.","Conversion increases common share count by ~54.9M, potentially dilutive to existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136002,"accession_number":"0001104659-25-086669","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Precigen secures up to $125M non-dilutive senior secured loan financing from Pharmakon","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M funded at close; $25M delayed draw available through June 2027; matures Sept 2030.","Interest at three-month SOFR (3.75% floor) + 6.50%, payable quarterly; amortization begins Sept 2028.","Proceeds to support U.S. commercialization of PAPZIMEOS and potential expansion into international and pediatric indications.","Loan is senior secured by substantially all U.S. assets, including IP; customary covenants and events of default.","CFO states strengthening balance sheet provides financial flexibility as company enters projected significant growth period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136001,"accession_number":"0001104659-25-079497","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Precigen announces FDA approval of PAPZIMEOS (no further details)","summary_kind":"llm","event_type":"regulatory","confidence":"medium","bullets":["US FDA approval of PAPZIMEOS announced via slide deck at August 18, 2025 investor webcast.","No additional specifics such as indication or market size provided in this filing.","The approval represents a significant regulatory milestone for Precigen (PGEN)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136000,"accession_number":"0000950103-25-010408","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-08-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Precigen enters into commercial supply agreement with Catalent for PAPIZEMOS manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement dated August 13, 2025 with Catalent Maryland for fill/finish services for gene therapy PAPIZEMOS (PRGN-2012).","Precigen grants Catalent exclusive rights for external commercial fill/finish manufacturing of the product in the Territory.","Initial term of three years, automatically renews annually unless 12-month termination notice given.","Precigen commits to minimum batch purchases per contract year as specified in the Plan Document.","Pricing subject to annual adjustment based on labor, utilities, and overhead costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153043,"accession_number":"0000950103-25-008124","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Precigen shareholders approve 300M share increase, re-elect directors, and expand equity plans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased authorized common shares by 300 million (223.2M votes for).","Randal J. Kirk approved to receive Series A Preferred Stock and Warrants as PIK dividends (167.4M for).","2023 Omnibus Incentive Plan expanded by 11.5M shares; 2019 Non-Employee Plan expanded by 1.1M shares.","All nine director nominees elected; top vote-getter Helen Sabzevari with 177.9M votes.","Deloitte ratified as auditor (228.9M for); advisory say-on-pay passed (175.9M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153042,"accession_number":"0000950103-25-006004","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q1 net loss $54.2M; PRGN-2012 BLA under FDA priority review with PDUFA Aug 27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $54.2M ($0.18/share) vs $23.7M ($0.10) YoY; includes $32.5M non-cash warrant liability fair value change.","Cash and investments $81.0M as of March 31, 2025; Q1 cash burn $16.9M; runway into 2026.","BLA for PRGN-2012 (RRP) under FDA priority review; PDUFA target action date August 27, 2025.","Pivotal study: 51% complete response, 86% reduction in surgeries; median follow-up 30 months.","Selected EVERSANA for commercialization support; advancing launch readiness for potential 2025 launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":1341000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171821,"accession_number":"0000950103-25-003637","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen reports FY2024 net loss of $126M; FDA priority review for PRGN-2012 BLA","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA for PRGN-2012 with priority review; PDUFA target date Aug 27, 2025.","Pivotal study: 51% complete response (no surgeries), durable beyond 12 months (median 24 months).","FY2024 net loss $126.2M ($0.47/share) vs $95.9M in 2023; revenue down 37% to $3.9M.","Cash, equivalents, investments $97.9M; runway extended into 2026 beyond potential launch.","Raised $87.5M in Dec 2024 from convertible preferred stock ($79M) and IP/royalty sale ($8.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171820,"accession_number":"0000950103-25-000576","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Precigen regains Nasdaq bid price compliance, delisting risk resolved","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Precigen on Jan 16, 2025 that it regained compliance with the $1.00 minimum bid price rule.","Stock closed at or above $1.00 for 10 consecutive business days from Dec 31, 2024 to Jan 15, 2025.","This resolves the deficiency first disclosed on Nov 1, 2024; the matter is closed.","No further action needed; company avoids potential delisting from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188827,"accession_number":"0000950103-24-018479","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-12-30T23:59:59+00:00","items":["1.01","8.01","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Precigen completes BLA submission for PRGN-2012 and raises $79M in private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Submitted BLA to FDA for PRGN-2012 (RRP), requesting priority review; 60-day review period to determine acceptance.","Phase 1/2 pivotal study: >50% of patients achieved Complete Response; >85% had fewer surgeries in year post-treatment.","Raised $79M gross from sale of 8% Series A Convertible Perpetual Preferred Stock and warrants to purchase 52.7M shares at $0.75.","Investors include Randal Kirk, Patient Capital Management, Bill Miller; proceeds for working capital and general corporate purposes.","Cash runway extends into 2026, beyond potential commercial launch in H2 2025 if PRGN-2012 is approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188826,"accession_number":"0000950103-24-018350","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Precigen sells FCX-007 assets for $8.5M cash, exits Castle Creek collaboration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Asset Acquisition Agreement with Innovator 21 (Paragon affiliate) closed Dec 24, 2024 for $8.5M cash.","Sold IP and royalty rights related to FCX-007, a clinical-stage candidate for Epidermolysis Bullosa.","Precigen has no further rights or obligations to Castle Creek or retained product royalties.","Proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188825,"accession_number":"0000950103-24-016317","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q3 net loss widens to $24M; on track for Q4 PRGN-2012 BLA submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $24.0M ($0.09/sh) vs $19.8M loss YoY; nine-month loss $106.5M ($0.41/sh).","Completed pre-BLA meeting with FDA; full alignment on BLA content for PRGN-2012 in RRP; rolling submission planned Q4 2024.","Commercial and manufacturing readiness underway for potential 2025 launch of PRGN-2012.","Confirmatory trial for PRGN-2012 initiated; end of Phase 1b meeting for PRGN-3006 in AML expected early 2025.","August 2024 equity offering raised net $30.9M; workforce reduced by over 20%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188824,"accession_number":"0000950103-24-016076","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Precigen receives Nasdaq bid price deficiency notice; has until Apr 30, 2025 to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $1 for 30 consecutive business days; compliance deadline April 30, 2025.","To regain compliance, bid price must close at $1+ for at least 10 consecutive business days.","If not compliant by deadline, may qualify for additional 180-day period if transferred to Nasdaq Capital Market and meets other standards.","Company may consider reverse stock split to cure deficiency; no assurance of compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188823,"accession_number":"0000950103-24-014811","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Precigen terminates Alaunos license agreement, regains all rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Amended and Restated License Agreement with Alaunos effective Oct 4, 2024.","Precigen regains all rights previously licensed to Alaunos under the agreement.","Alaunos retains no rights to use any Precigen technology.","Original A&R License Agreement was entered into on April 3, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205306,"accession_number":"0000950103-24-013816","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Precigen SVP of Intellectual Property Affairs Jeffrey Perez to depart Nov 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey Perez, SVP of Intellectual Property Affairs, will separate from Precigen effective November 1, 2024.","Perez is expected to remain in his current role through the separation date for transition purposes.","Severance payments and benefits will be provided under his existing employment agreement dated April 2, 2019."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205305,"accession_number":"0000950103-24-012981","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Precigen grants PSUs tied to PRGN-2012 BLA milestones to named execs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Target PSUs granted: CEO Helen Sabzevari 1,650,000; CFO Harry Thomasian 250,000; COO Rutul Shah 250,000; CLO Donald Lehr 108,000.","Vesting in two 50% installments upon: (1) FDA submission of BLA for PRGN-2012, (2) FDA approval of BLA, both by Dec 31, 2026.","PSUs forfeited if milestones not achieved by end of Performance Period; vesting accelerated upon change in control in certain cases.","Pro-rata vesting applies on termination without cause or for good reason; full forfeiture on other termination events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205304,"accession_number":"0000950103-24-012201","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q2 net loss widens to $58.8M; pivots to PRGN-2012 with BLA submission planned H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 net loss of $58.8M ($0.23/share) vs $20.3M loss a year ago; includes impairment charge of $32.9M.","Total revenues fell 59% YoY to approx $0.8M; R&D expenses rose 32% on severance and PRGN-2012 trial costs.","Strategic reprioritization focuses on PRGN-2012 BLA submission under accelerated path H2 2024; workforce reduced >20%.","Appointed Phil Tennant as CCO for potential PRGN-2012 commercial launch; raised $31.4M net in August public offering.","Cash runway expected into early 2025; ActoBio subsidiary shut down, IP portfolio available for sale."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205303,"accession_number":"0001104659-24-087596","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Precigen raises ~$31.4M net in underwritten public offering of 35.3M shares at $0.85","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Precigen entered into underwriting agreement with Stifel for offering of 35,294,118 shares at $0.85/share.","Underwriters have 30-day option for up to 5,294,117 additional shares; 4,584,821 shares exercised.","Net proceeds approximately $31.4 million after underwriting discounts and estimated expenses.","Offering made under shelf registration statement declared effective January 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205302,"accession_number":"0001104659-24-086275","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Precigen reports $19.5M cash, $32.9M impairment, $30M offering, >20% workforce cut","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash $19.5M at June 30, 2024; non-cash impairment charges ~$32.9M and severance ~$3.0M in Q2/Q3.","Strategic pivot to PRGN-2012 gene therapy; rolling BLA submission expected H2 2024; ActoBio subsidiary shutdown.","Commences $30M underwritten public offering (plus $4.5M option); expects net proceeds plus cash to fund ops into early 2025.","Workforce reduced >20%; PRGN-2009 non-NCI sites paused; UltraCAR-T programs paused except PRGN-3006; preclinical halted.","PRGN-2012 confirmatory trial initiated; commercial readiness led by new CCO; revenue not reported (pre-revenue stage)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205301,"accession_number":"0000950103-24-009693","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Precigen elects Nancy Howell Agee to board; shareholders approve 2M share increase in incentive plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dean Mitchell's term ended July 5, 2024; he did not stand for re-election, no disagreement cited.","Nancy Howell Agee elected to the board effective July 5, 2024.","Shareholders approved amendment to 2023 Omnibus Incentive Plan increasing shares available by 2,000,000.","All director nominees elected with majority support; Deloitte & Touche ratified as auditor; say-on-pay passed.","Vote results: Randal Kirk received 146,479,803 for; other directors similarly elected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222192,"accession_number":"0000950103-24-006675","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen Q1 net loss $23.7M, revenue down 43%; PRGN-2012 BLA submission on track for H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.7M ($0.10 EPS) vs $22.7M; total revenue down 43% YoY to approx. $1.06M.","Cash, equivalents, and short-term investments $44.8M; evaluating financing options to strengthen balance sheet.","PRGN-2012 pivotal Phase 2 data as late-breaking oral at ASCO June 3; rolling BLA submission expected H2 2024.","Commercial readiness activities underway for potential PRGN-2012 launch in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241709,"accession_number":"0000950103-24-004017","cik":1356090,"company_name":"PRECIGEN, INC.","ticker":"PGEN","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Precigen reports FY2023 loss of $95.9M; plans BLA submission for PRGN-2012 in H2 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 revenue $6.2M, down 77% YoY; net loss $95.9M ($0.39 loss per share).","Cash and investments $62.9M; SG&A down 16% to support cost containment.","Plans to submit BLA for PRGN-2012 under accelerated approval in H2 2024; potential launch 2025.","PRGN-2009 IND cleared Phase 2 in cervical cancer; interim data for PRGN-3006 and PRGN-3007 expected H2 2024.","Recorded $10.4M goodwill impairment charge for Exemplar subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1600734226.7272727,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}